The FAS ligand or FasL is a type II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Some alternate names include Fas ligand, FasL, apoptosis antigen ligand 1, CD95 ligand. It is a trimeric molecule. NIGGGGGGGGAAAAAAAAAAAAAAAA PLEASE A transmembrane protein is an integral membrane protein that spans from the internal to the external surface of the biological membrane or lipid bilayer in which it is embedded. ... In medicine, tumor necrosis factor alpha (TNFα, cachexin or cachectin) is an important cytokine involved in systemic inflammation and the acute phase response. ...
This trimerization will possibly leading to apoptosis, or cell death.
Defective Fas mediated apoptosis may lead to oncogenesis as well as drug resistance in existing tumors. Germline mutation of Fas is asociated with Autoimmune Lymphoproliferative Syndrome (ALPS) (OMIM #601859), a childhood disorder of apoptosis. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?cmd=entry&id=601859 http://www.clinicaltrials.gov/ct/show/NCT00001350
Strong Fas expression was correlated with depth of invasion (40.3% in pT1,T2 versus 20.5% in pT3,T4; P = 0.0308), histological differentiation (45.7% in well versus 25.4% in nonwell; P = 0.0347), and lymph node metastasis (22.6% in positive versus 45.5% in negative; P = 0.0129).
Fas expression was one of the independent favorable prognosticators for patients' survival (risk ratio, 3.26; P = 0.0103) in esophageal SCC.
Fas expression was an independent prognosticator for recurrence-free survival, whereas FasL expression did not influence the survival in esophageal squamous cell carcinoma.
Feeds |
Contact